Novartis eyes a new market with its buyout of a small digital therapeutics player

Novartis has scooped up a digital therapeutics player working on a new treatment for lazy eye.

The company is Phoenix-based Amblyotech, which has been pursuing work on a combination gaming and video approach to training eyes to work together. But the buyer and private seller are keeping the terms to themselves.